Expression of gonadotropin-releasing hormone receptor mRNA in the rat ventral prostate and Dunning R3327 PAP adenocarcinoma before and after castration

Prostate

Volumn 39, Issue 2, 1999, Pages 101-107

  Tieva, Åse ^a   Wikström, Pernilla ^a   Olofsson, Jan I ^a   Bergh, Anders ^a   Damber, Jan Erik ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

Castration; Com petitive reverse transcription polymerase chain reaction; GnRH R; Prostatic adenocarcinoma; Ventral prostate

Indexed keywords

ANDROGEN; GONADORELIN RECEPTOR; GONADOTROPIN; MESSENGER RNA;

ANDROGEN RELEASE; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CASTRATION; CONTROLLED STUDY; FEMALE; GONADOTROPIN BLOOD LEVEL; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE VENTRAL LOBE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY;

ADENOCARCINOMA; ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; RATS; RATS, INBRED F344; RECEPTORS, LHRH; RNA, MESSENGER;

EID: 0033119894     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19990501)39:2<101::AID-PROS4>3.0.CO;2-J     Document Type: Article

References (44)

1. Conn MP, Crowley WW. Gonadotropin-releasing hormone and its analogs. Annu Rev Med 1994;45:391-405.
2. Cunha GR, Donjacour AA, Cooke PS, Mee S, Bigsby RM, Higgins SJ, Sugimura Y. The endocrinology and developmental biology of the prostate. Endocr Rev 1987;8:338-362.
3. Walsh PC. Physiological basis for hormonal therapy in carcinoma of the prostate. Urol Clin North Am 1975;2:125-140.
4. Grayhack JT, Keeler TC, Kozlowski JM. Carcinoma of the prostate. Hormonal therapy. Cancer 1987;60:589-601.
5. Clayton NR. Gonadotropin releasing hormone: from physiology to pharmacology. Clin Endocrinol (Oxf) 1987;26:361-384.
6. Schally AV. Hypothalamic hormones: from neuroendocrinology to cancer therapy. Anticancer Drugs 1994;5:115-130.
7. Emons G, Schally AV. The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. Hum Reprod Upd 1994;9:1364-1379.
8. Kyprianou N, Isaacs JT. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 1988;122: 552-562.
9. Belchetz EP. Gonadotrophin regulation and clinical applications of GnRH. J Clin Endocrinol Metab 1983;12:619-640.
10. Emons G, Ortmann O, Becker M, Irmer G, Springer B, Laun R, Hölzel F, Schulz K-D, Schally AV. High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res 1993;53:5439-5446.
11. Minaretzis D, Jakubowski M, Mortola JF, Pavlou SN. Gonadotropin-releasing hormone receptor gene expression in human ovary and granulosa-lutein cells. J Clin Endocrinol Metab 1995; 80:430-434.
12. Imai A, Takagi H, Horibe S, Fuseya T, Tamaya T. Coupling of gonadotropin-releasing hormone receptor to Gi protein in human reproductive tract tumors. J Clin Endocrinol Metab 1996; 81:3249-3253.
13. Kakar SS, Grizzle WE, Neill JD. The nucleotide sequences of human GnRH receptors in breast and ovarian tumors are identical with that found in pituitary. Mol Cell Endocrinol 1994;106: 145-149.
14. Kottler M-L, Starzec A, Carre M-C, Lagarde J-P, Martin A, Counis R. The genes for gonadotropin-releasing hormone and its receptor are expressed in human breast with fibrocystic disease and cancer. Int J Cancer 1997;71:595-599.
15. Eidne KA, Flanagan CA, Millar RP. Gonadotropin-releasing hormone binding sites in human breast carcinomas. Science 1985;229:989-991.
16. Sion-Vardi N, Kaneti J, Segal-Abramson T, Giat J, Levy J, Sharoni Y. Gonadotropin-releasing hormone specific binding sites in normal and malignant renal tissue. J Urol 1992;148:1568-1570.
17. Emons G, Schröder B, Ortmann O, Westphalen S, Schultz K-D, Schally AV. High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. J Clin Endocrinol Metab 1993; 77:1458-1464.
18. Chatzaki E, Bax CMR, Eidne KA, Anderson L, Grudzinskas JG, Gallagher CJ. The expression of gonadotropin-releasing hormone and its receptor in endometrial cancer, and its relevance as an autocrine growth factor. Cancer Res 1996;56:2059-2065.
19. Bramley TA, McPhie CA, Menzies GS. Human placental gonadotrophin-releasing hormone (GnRH) binding sites: III. Changes in GnRH binding levels with stage of gestation. Placenta 1994;15:733-745.
20. Qayum A, Gullick W, Clayton RC, Sikora K, Waxman J. The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumour receptors. Br J Cancer 1990;62:96-99.
21. Dondi D, Limonta P, Moretti RM, Marelli MM, Garattini E, Motta M. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop, Cancer Res 1994;54:4091-4095.
22. Limonta P, Dondi D, Moretti RM, Maggi R, Motta M. Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab 1992;75:207-212.
23. Srkalovic G, Bokser L, Radulovic S, Korkut E, Schally VA. Receptors for luteinizing hormone-releasing hormone (LHRH) in Dunning R3327 prostate cancers and rat anterior pituitaries after treatment with a sustained delivery system of LHRH antagonist SB-75. Endocrinology 1990;127:3052-3060.
24. Szende B, Takács J, Mezô I, Szegedi Z, Kéri G. Binding of a radiolabeled tumor selective GnRH analog to PC-3 human prostate cancer cells and the induction of apoptosis. Endocrine 1994; 2:645-649.
25. Limonta P, Dondi D, Moretti MR, Fermo D, Garattini E, Motta M. Expression of luteinizing hormone-releasing hormone mRNA in the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab 1993;76:797-800.
26. Landström M, Damber J-E, Bergh A, Tomic R. Dose/response study of the effects of oestrogens on tumor growth and morphology in the Dunning R3327 prostatic adenocarcinoma. J Cancer Res Clin Oncol 1992;118:30-34.
27. Celi FS, Zenilman ME, Shuldiner AR. A rapid and versatile method to synthesize internal standards for competitive PCR. Nucleic Acids Res 1993;21:1047.
28. Wikström P, Bergh A, Damber J-E. Expression of transforming growth factor-receptor type I and type II in rat ventral prostate and Dunning R3327 PAP adenocarcinoma in response to castration and oestrogen treatment. Urol Res 1997;25:103-111.
29. Danielson EP, Forss-Petter S, Brow MA, Calavetta L, Douglass J, Milner RJ, Sutcliff JG. p1B15: a cDNA clone of the rat mRNA encoding cyclophilin. DNA 1988;7:261-267.
30. Moumni M, Kottler M-L, Counis R. Nucleotide sequence analysis of mRNAs predicts that rat pituitary and gonadal gonadotropin-releasing hormone receptor proteins have identical primary structure. Biochem Biophys Res Commun 1994;200:1359-1366.
31. Imai A, Ohno T, Iida K, Fuseya T, Furui T, Tamaya T. Gonadotropin-releasing hormone receptor in gynecologic tumors: frequent expression in adenocarcinoma histologic types. Cancer 1994;74:2555-2561.
32. Yano T, Pinski J, Szepeshazi K, Milanovic SR, Groot K, Schally AV. Effect of microcapsules of luteinizing hormone-releasing hormone antagonist SB-75 and somatostatin analog RC-160 on endocrine status and tumor growth in the Dunning R-3327H rat prostate cancer model. Prostate 1992;20:297-310.
33. Szepeshazi K, Korkut E, Szende B, Lapis K, Schally AV. Histological changes in Dunning prostate tumors and testes of rats treated with LH-RH antagonist SB-75. Prostate 1991;18:255-270.
34. Redding TW, Schally AV, Radulovic S, Milovanovic S, Szepeshazi K, Isaacs JT. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice. Cancer Res 1992;52:2538-2544.
35. Blankenstein MA, Henkelman MS, Klijn JGM. Direct inhibitory effect of a luteinizing hormone-releasing hormone agonist on MCF-7 human breast cancer cells. Eur J Cancer Clin Oncol 1985; 21:1493-1499.
36. Manetta A, Gamboa-Vujicic G, Paredes P, Emma D, Liao S, Leong L, Asch B, Schally AV. Inhibition of growth of human ovarian cancer in nude mice by luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75). Fertil Steril 1995;63: 282-287.
37. Westin P, Brändström A, Damber J-E, Bergh A. Castration plus oestrogen treatment induces but castration alone suppresses epithelial cell apoptosis, in an androgen-sensitive rat prostatic adenocarcinoma. Br J Cancer 1995;72:140-145.
38. Westin P, Bergh A, Damber J-E. Castration rapidly results in a major reduction in epithelial cell number in the rat prostate, but not in the highly differentiated Dunning R3327 prostatic adenocarcinoma. Prostate 1993;22:65-74.
39. Azad N, Uddin S, Paglia NL, Kirstein L, Emanuele NV, Lawrence MA, Kelley MR. Luteinizing hormone-releasing hormone (LHRH) in rat prostate: characterization of LHRH peptide, messenger ribonucleic acid expression, and molecular processing of LHRH in intact and castrated male rats. Endocrinology 1993;133:1252-1257.
40. Olofsson JI, Conti CC, Leung PCK. Homologous and heterologous regulation of gonadotropin-releasing hormone receptor gene expression in preovulatory rat granulosa cells. Endocrinology 1995;136:974-980.
41. Peng C, Fan N, Ligier M, Väänänen J, Leung PCK. Expression and regulation of GnRH and GnRH receptor mRNAs in human granulosa-luteal cells. Endocrinology 1994;135:1740-1746.
42. White RB, Eisen JA, Kasten TL, Fernald RD. Second gene for gonadotropin-releasing hormone in humans. Proc Natl Acad Sci USA 1998;95:305-309.
43. Hershkovitz E, Marbach M, Bosin E, Levy J, Roberts CT, LeRoith D, Schally AV, Sharoni Y. Luteinizing hormone-releasing hormone antagonists interfere with autocrine and paracrine growth stimulation of MCF-7 mammary cancer cells by insulin-like growth factors. J Clin Endocrinol Metab 1993;77:963-968.
44. Haendler B, Hofer B. Characterization of the human cyclophilin gene and of related pseudogenes. Eur J Biochem 1990;190:477.